Salhia Real Estate Company K.S.C.P. (KWSE:SRE)

Ligand Pharmaceuticals Income Statement

Financials in millions KWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	44.98	44.69	40.59	35.94	21.07	19.35
Revenue Growth (YoY)	7.26%	10.11%	12.94%	70.59%	8.90%	-56.64%
Cost of Revenue	10	10.02	9.33	8.82	4.87	8.73
Gross Profit	34.98	34.67	31.26	27.12	16.2	10.62
Selling, General & Admin	5.02	5.24	5.12	4.66	4.2	4.38
Other Operating Expenses	0.3	0.33	0.42	0.38	0.25	0.56
Operating Expenses	13.71	13.77	11.73	10.5	7.95	9.99
Operating Income	21.27	20.9	19.53	16.62	8.25	0.63
Interest Expense	-0.39	-	-	-2.83	-0.51	-0.5
Interest & Investment Income	0.15	0.17	0.06	0.55	0.03	0.47
Earnings From Equity Investments	0.38	1.61	2.67	2.33	0	-0.57
Currency Exchange Gain (Loss)	0.33	0.33	-0.02	0.17	0.03	0
Other Non Operating Income (Expenses)	-10.96	-10.77	-6.08	0.05	0.37	0.4
EBT Excluding Unusual Items	10.79	12.25	16.15	16.89	8.16	0.44
Gain (Loss) on Sale of Assets	0.62	0.62	0.54	-	1.36	21.88
Asset Writedown	0.12	0.12	-1.03	-1.67	-	-0.62
Other Unusual Items	-0.12	-0.13	-0.17	-0.15	0.11	-0.22
Pretax Income	11.42	12.86	16.24	15.06	9.63	21.48
Income Tax Expense	0.12	0.13	0.17	0.49	0.28	0.24
Earnings From Continuing Operations	11.31	12.73	16.08	14.57	9.35	21.23
Minority Interest in Earnings	-0.1	-0.11	-0.06	-0.01	-0	0.08
Net Income	11.2	12.62	16.01	14.56	9.35	21.31
Net Income to Common	11.2	12.62	16.01	14.56	9.35	21.31
Net Income Growth	-25.91%	-21.16%	9.95%	55.76%	-56.14%	-0.94%
Shares Outstanding (Basic)	603	603	604	598	603	602
Shares Outstanding (Diluted)	603	603	604	598	603	602
Shares Change (YoY)	-0.11%	-0.16%	0.93%	-0.78%	0.21%	0.57%
EPS (Basic)	0.02	0.02	0.03	0.02	0.02	0.04
EPS (Diluted)	0.02	0.02	0.03	0.02	0.02	0.04
EPS Growth	-25.82%	-21.04%	8.94%	56.98%	-56.23%	-1.50%
Free Cash Flow	1.02	14.09	15.88	21.28	9.3	17.07
Free Cash Flow Per Share	0.00	0.02	0.03	0.04	0.01	0.03
Dividend Per Share	0.014	0.014	0.014	0.013	0.012	0.025
Dividend Growth	5.15%	5.15%	4.61%	4.84%	-49.80%	19.90%
Gross Margin	77.77%	77.58%	77.01%	75.46%	76.89%	54.89%
Operating Margin	47.29%	46.77%	48.11%	46.25%	39.14%	3.27%
Profit Margin	24.90%	28.24%	39.45%	40.52%	44.37%	110.17%
Free Cash Flow Margin	2.26%	31.52%	39.14%	59.21%	44.13%	88.22%
EBITDA	29.66	29.1	25.71	21.99	11.55	5.28
EBITDA Margin	65.94%	65.12%	63.35%	61.18%	54.84%	27.27%
D&A For EBITDA	8.39	8.2	6.18	5.37	3.31	4.64
EBIT	21.27	20.9	19.53	16.62	8.25	0.63
EBIT Margin	47.29%	46.77%	48.11%	46.25%	39.14%	3.27%
Effective Tax Rate	1.04%	1.04%	1.04%	3.26%	2.88%	1.14%

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.